GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years and as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

GAMMAGARD LIQUID Product Characteristics

Not all intravenous immune globulin (IVIG) formulations are interchangeable1-3

The final formulation can differ among IVIGs, meaning they are not interchangeable.1,3 When selecting an IVIG treatment, individual patient characteristics should be considered.1,3

IVIG treatments are distinct plasma products with patient tolerance differing from one brand to another. Not all IVIG treatments are biologically equivalent, and caution should be used when changing products.1,3

Patient conditions and risk factors to consider with IVIG administration

Predisposition for renal insufficiency1,4-6

Patient risk factors (this is not an all-inclusive list)

  • Diabetes mellitus
  • Elderly
  • Hypovolemia
  • Sepsis
  • Paraproteinemia
  • Concomitant therapy with nephrotoxic drugs

IVIG risk factors1,7

Sodium content Sugar content Osmolality lgA Volume load

Heart disease1,8-10

Patient risk factors (this is not an all-inclusive list)

  • Thromboembolic risk factors
  • Coronary artery disease
  • Heart failure
  • Hypertension
  • Hyperlipidemia
  • Cardiovascular risk factors

IVIG risk factors1,7

Sodium content Sugar content Osmolality lgA Volume load

Diabetes mellitus5

Patient risk factors (this is not an all-inclusive list)

  • Type 1
  • Type 2

IVIG risk factors1,7

Sodium content Sugar content Osmolality lgA Volume load

Elderly1,11

Patient risk factors (this is not an all-inclusive list)

  • Generally considered as >65 years of age

IVIG risk factors1,7

Sodium content Sugar content Osmolality lgA Volume load

IgA deficiency1

Patient risk factors (this is not an all-inclusive list)

  • IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
  • All patients, since an IgA concentration that will provoke a reaction is unknown; even trace amounts of IgA present a risk of anaphylaxis

IVIG risk factors1,7

Sodium content Sugar content Osmolality lgA Volume load

Volume intake restrictions1,9

Patient risk factors (this is not an all-inclusive list)

  • Hyperviscosity risk factors
  • Cardiac impairment
  • Renal impairment
  • Pulmonary edema
  • Hypertension
  • Elderly

IVIG risk factors1,7

Sodium content Sugar content Osmolality lgA Volume load

GAMMAGARD LIQUID is formulated with patient needs in mind12

No sodium added icon.

No added sodium

No sugar added icon.

No added sugar

No preservatives icon.

No preservatives

No latex icon.

No latex

Test tube icon.

Osmolality 240-300 mOsmol/kg, similar to physiologic levels

Graph showing an increase.

IgA average
concentration of
37 µg/mL

pH range icon.

pH range of 4.6-5.1

Graph showing glycine stabilizing.

Glycine stabilized

GAMMAGARD LIQUID vials.

GAMMAGARD LIQUID is designed
for ease of use

GAMMAGARD LIQUID offers convenient vial size options and storage with no refrigeration required.12

See vial and storage info

Review the product characteristics for 12 IVIG treatments

Review the product characteristics of 12 distinct IVIG treatments. Download to save or print for easy reference. Please note, this chart provides product characteristics only and does not imply clinical outcomes.

Download product characteristics chart
Man typing on a keyboard.
Primary Immunodeficiency icon.

Review details for GAMMAGARD LIQUID specific to Primary Immunodeficiency (PI)

PI information
Multifocal Motor Neuropathy icon.

Review details for GAMMAGARD LIQUID specific to Multifocal Motor Neuropathy (MMN)

MMN information